TorreyPines Therapeutics Reports Third Quarter 20...(rch and development 8161 4470 ...)

General and administrative 1,351 680 4,209 1,986

Total operating expenses 9,512 5,150 24,599 19,626

Loss from operations (7,049) (2,687) (17,211) (12,238)

Other income (expense)

Interest income 504 259 1,699 732

Interest expense (193) (279) (647) (735)

Other income (expense), net (36) - 946 2

Total other income (expense) 275 (20) 1,998 (1)

Net loss (6,774) (2,707) (15,213) (12,239)

Dividends and accretion

to redemption value of

redeemable convertible

preferred stock - (1,237) - (3,534)

Net loss attributable

to common stockholders $(6,774) $(3,944) $(15,213) $(15,773)

Basic and diluted net

loss per share

attributable to common

stockholders* $(0.43) $(7.18) $(0.97) $(29.19)

Weighted average shares

used in the computation

of basic and diluted net

loss per share

attributable to

common stockholders *15,733,970 549,481 15,711,212 540,395

* Basic and diluted net loss per share attributable to common

stockholders and weighted average shares outstanding were impacted by

the conversion of preferred stock and issuance of common stock in

connection with the Axonyx merger.